Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

NCT01513460 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

773

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: NVA237 50µg once daily
DRUG: Tiotropium 18µg once daily
DRUG: Flu/Sal
DRUG: NVA237 placebo + Tiotropium placebo.

Sponsor

Novartis Pharmaceuticals